Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference

  Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor
                                  Conference

PR Newswire

CASTLE ROCK, Colo., May 21, 2014

CASTLE ROCK, Colo., May 21, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY),
an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based
assay for identifying patients that are at low risk for appendicitis, today
announced it will participate in the 11^th Annual Craig-Hallum Institutional
Investor Conference, to be held May 28, 2014, at the Minneapolis Marriott City
Center.

Steve Lundy, President and CEO of Venaxis™ will be available to participate in
one-on-one meetings during the full-day conference. Investors who wish to
request a meeting with Venaxis should contact their Craig-Hallum
representative.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, an initial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking
statements. These statements are based on certain assumptions made based on
experience, expected future developments and other factors Venaxis believes
are appropriate in the circumstances. Such statements are subject to a number
of assumptions, risks and uncertainties, many of which are beyond the control
of Venaxis. Investors are cautioned that any such statements are not
guarantees of future performance. Actual results or developments may differ
materially from those projected in the forward-looking statements as a result
of many factors, including our ability to obtain FDA clearance or approval,
maintain CE Marking, cost effectively manufacture and generate revenues from
the APPY1 Test at a profitable price point, execute agreements required to
successfully advance the company's objectives, retain the management team to
advance the products, overcome adverse changes in market conditions and the
regulatory environment, obtain and enforce intellectual property rights, and
realize value of intangible assets. Furthermore, Venaxis does not intend (and
is not obligated) to update publicly any forward-looking statements. The
contents of this press release should be considered in conjunction with the
risk factors contained in Venaxis' recent filings with the SEC, including its
Form 10-K for the year ended December 31, 2013, filed with the SEC on March
28, 2014.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD, jdrumm@tiberend.com; (212) 375-2664
Claire Sojda, csojda@tiberend.com; (212) 375-2686

SOURCE Venaxis, Inc.

Website: http://www.venaxis.com
 
Press spacebar to pause and continue. Press esc to stop.